Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics (Nasdaq: RPTX) shareholders approved a statutory plan of arrangement to be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. at a special meeting held January 16, 2026. The arrangement resolution passed with 99.76% of votes cast. Shareholders also approved, on an advisory basis, executive compensation tied to the deal (99.34%) and contingency liquidation and liquidator appointment votes (99.75% each). The arrangement remains subject to the Superior Court of Québec final order, with a hearing scheduled for January 23, 2026 and closing expected on or about January 28, 2026, subject to customary conditions.
Repare Therapeutics (Nasdaq: RPTX) announced a definitive asset purchase agreement under which Gilead Sciences will acquire Repare’s Polθ ATPase inhibitor, RP-3467, for up to $30 million in total consideration.
Deal terms include a $25 million upfront payment subject to customary holdbacks and adjustments and an additional $5 million payable upon completion of specified technology transfer activities. Repare said the upfront cash increases its estimated Closing Net Cash Amount under a separate arrangement in which Xeno will acquire Repare, and Repare now estimates a cash payment of approximately US$2.20 per common share at the Arrangement Closing.
Repare Therapeutics (Nasdaq: RPTX) announced that certain affiliates of BVF Partners, Blue Owl Healthcare Opportunities, and OrbiMed have entered into support and voting agreements to vote their common shares in favor of the proposed transaction with XenoTherapeutics, Inc. and Xeno Acquisition Corp.
The arrangement follows a definitive arrangement agreement announced on November 14, 2025 under which Xeno will acquire all issued and outstanding common shares of Repare. Combined with prior director and executive officer agreements, shareholders owning approximately 40% of Repare’s outstanding common shares have agreed to vote for the special resolution approving the transaction.
Repare Therapeutics (Nasdaq: RPTX) entered into a definitive arrangement agreement to be acquired by XenoTherapeutics with an estimated cash payment of $1.82 per share plus one non-transferable CVR per share. The CVR entitles holders to specified percentages of future partnership and disposition proceeds over up to a 10-year period and 100% of certain near-term receivables.
The Transaction is expected to close in Q1 2026, is subject to shareholder and court approvals, and would result in delisting and deregistration. Repare reported $112.6M cash and marketable securities as of September 30, 2025, Q3 2025 revenue from collaborations of $11.6M, and net income of $3.3M for the quarter.
Repare Therapeutics (Nasdaq: RPTX) will present initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS trial of RP-1664 at the 37th AACR-NCI-EORTC conference in Boston on October 25, 2025. The LIONS trial (NCT06232408) is a first-in-human, multicenter, open-label Phase 1 study evaluating safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of RP-1664, an oral PLK4 inhibitor, in adult and adolescent patients with TRIM37-high solid tumors.
The poster (Abstract LB-C002) will be presented by Benjamin Herzberg, MD on Saturday, October 25, 12:30–4:00 PM ET in Poster Session C; a copy will be posted on Repare's Scientific Resources page at session start.
Repare Therapeutics (NASDAQ:RPTX) announced significant business developments and Q2 2025 financial results. The company secured a major worldwide licensing agreement with Debiopharm for lunresertib, potentially worth up to $257 million in milestone payments plus royalties. Additionally, Repare out-licensed its discovery platforms to DCx Biotherapeutics, receiving a $1 million upfront payment and a 9.99% equity position.
The company maintains $109.5 million in cash and expects key clinical data readouts in Q4 2025 from both the LIONS trial (RP-1664) and POLAR trial (RP-3467). Net loss for Q2 2025 was $16.7 million ($0.39 per share), an improvement from $34.8 million in Q2 2024. The company is actively exploring strategic alternatives to maximize shareholder value.
Repare Therapeutics (NASDAQ:RPTX) has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class PKMYT1 inhibitor for precision oncology. Under the agreement, Repare will receive a $10 million upfront payment and is eligible for up to $257 million in potential milestones, plus single-digit royalties on global sales.
The agreement builds on their existing collaboration studying lunresertib's combination with Debio 0123, a WEE1 inhibitor. Debiopharm will take over the MYTHIC study and future development of lunresertib. Repare will focus on advancing two Phase 1 clinical trials: the LIONS trial evaluating RP-1664 (PLK4 inhibitor) and the POLAR trial evaluating RP-3467 (Polθ ATPase inhibitor), with readouts expected in Q3-Q4 2025.
DCx's strategy focuses on developing MM-ADCs that target both intracellular and cell-surface targets to improve efficacy, prolong activity, and enhance tolerability compared to traditional ADCs that use broadly chemotoxic payloads.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
